Patent application number | Description | Published |
20130053366 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION - Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α | 02-28-2013 |
20130053367 | COMPOUNDS AND METHODS OF TREATING DIABETES - Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α | 02-28-2013 |
20130190294 | COMPOUNDS AND METHODS FOR TREATING DIABETES - Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α | 07-25-2013 |
20140088086 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION - Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α | 03-27-2014 |
20140179668 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF - Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer. | 06-26-2014 |
20150266884 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION - Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α | 09-24-2015 |
20150315188 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION - Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor α | 11-05-2015 |
20160068513 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF - Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer. | 03-10-2016 |